A Study of Eloralintide (LY3841136) in Participants With Obesity, or Overweight Without Type 2 Diabetes

Conditions

• Obesity
• Overweight

Eligibility Criteria

Sex

ALL

Age

18 Years - N/A

Healthy Volunteers

Not accepted

Interventions

• Eloralintide — DRUG
  Administered SC
• Placebo — DRUG
  Administered SC

Study Details

The purpose of this study is to evaluate the efficacy and safety of eloralintide in adults with obesity or overweight who do not have type 2 diabetes. The study has two phases: a main phase and an extension phase. Participation in the main phase of the study will last about 75 weeks. Participants with prediabetes will continue in the extension phase for another 2 years.

Key Dates

Start date

Feb 6, 2026

Status verified

Jun 2026

Primary completion

Mar 31, 2028

Completion

Jul 31, 2030

Study Design

Enrollment

1,980 participants (estimated)

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Arms

• Experimental: Eloralintide Dose 1
  Participants will receive eloralintide subcutaneously (SC)
• Experimental: Eloralintide Dose 2
  Participants will receive eloralintide SC
• Experimental: Eloralintide Dose 3
  Participants will receive eloralintide SC
• Experimental: Eloralintide Dose 4
  Participants will receive eloralintide SC
• Placebo Comparator: Placebo
  Participants will receive placebo SC

Primary Outcome Measure

Percent Change from Baseline in Body Weight [ Time Frame: Baseline, Week 64 ]

Central Contacts

• Trial question or participation questions: 1-877-CTLILLY (1-877-285-4559) or
  1-317-615-4559
  [email protected]
• Physicians interested in becoming principal investigators please contact
  [email protected]

Locations (41)

Find similar trials in Tuscaloosa, AL

Related Studies

• Diabetes and Heart Disease Risk in Blacks
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Physical and Behavioral Traits of Overweight and Obese Adults
  Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Bethesda, Maryland
• Effects of Brain Stimulation on Food Intake and Behavioral Weight Loss Treatment
  PHASE2 · Recruiting · National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) · Phoenix, Arizona
• Characterization of Patients With Uncommon Presentations and/or Uncommon Diseases Associated With the Cardiovascular System
  Recruiting · National Heart, Lung, and Blood Institute (NHLBI) · Washington D.C., District of Columbia